Morningstar
•
Oct 30, 2026
Fortrea Holdings Inc.: Fortrea Earnings: Strong Bookings Signal Improving Demand Trends
Summary
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
RVTY: Raising target price to $170.00
Oct 28, 2026
•
RVTY
PHIN: What does Argus have to say about PHIN?
Oct 28, 2026
•
PHIN
PRVA: Lowering target price to $21.00
Oct 28, 2026
•
PRVA
AZTA: Raising target price to $41.00
Oct 28, 2026
•
AZTA
VSTS: Raising target price to $16.00
Oct 28, 2026
•
VSTS
